Important Dates

  • 2023-10-01

    Abstract Submission and Travel Grant Application Open

  • 2023-10-01

    Early Bird Registration Opens

  • 2024-04-30

    Deadline for Abstract Submission and Travel Grant Application

  • 2024-05-15

    Notification of Abstract and Travel Grant Acceptance

  • 2024-05-31

    Deadline for Abstract Author Registration

  • 2024-05-31

    Deadline for Early Bird Registration

  • 2024-06-15

    Deadline for Online Standard Registration

Welcome Message

Dear colleagues, ladies and gentlemen,

On behalf of the organizing committee, it's my pleasure to extend a warm welcome to you to attend the APASL Single Topic Conference on Metabolic Associated Fatty Liver Disease (MAFLD) in the beautiful city of Kaohsiung, Taiwan, on June 28 – 30, 2024. I am honored to invite you to join our exploration of the latest advancements in the field of MAFLD.

We have curated an engaging program that includes keynote lectures, scientific sessions, panel discussions, and poster presentations with the main theme "MAFLD, More than A Fatty Liver Disease: Interplay between obesity, diabetes, cardiovascular diseases, HBV, HCV and HCC" in the field of MAFLD. Experts around the globe will be sharing their valuable insights and offering comprehensive perspectives exploring the latest developments in screening, diagnosis, assessment, pathogenesis and therapeutic approaches by participating in panel-based discussions on controversial topics and future clinical management in case-based multidisciplinary approaches. Together, we push beyond our limits of hepatological as well as multidisciplinary knowledges.

This will be a remarkable opportunity to learn from the best minds in the field establish fruitful connections for future collaborations.

Welcome to the APASL STC 2024 on MAFLD in Kaohsiung, Taiwan!

Ming-Lung Yu


Dear Ladies and gentlemen,

Thank you all for gracing us with your presence at the APASL Single Topic Conference on Metabolic Associated Fatty Liver Disease (MAFLD) hosted here in the beautiful city of Kaohsiung. We are truly honored to have you all here, including our esteemed colleagues from both domestic and international arenas. This three-day international symposium, running from June 28th to June 30th, promises to be a remarkable gathering of minds dedicated to the advancement of MAFLD research.

Over the course of these three days, we have curated an engaging program filled with insightful presentations, enlightening discussions, and invaluable networking opportunities. Our goal is to facilitate the sharing of groundbreaking research, innovative approaches, and clinical experiences that will contribute to the collective understanding and management of MAFLD.

Once again, we express our sincere gratitude to all attendees, speakers, and sponsors for their invaluable support in making this conference a reality. We are confident that this event will inspire new ideas, spark collaborations, and ultimately make a positive impact on the lives of individuals affected by MAFLD.

We look forward to welcoming you to the APASL STC 2024 on MAFLD in Kaohsiung, Taiwan!

Best regards,

Chun-Jen Liu

President, Taiwan Association for the Study of the Liver (TASL)

Dear Ladies and gentlemen,

Welcome to the APASL Single Topic Conference on Metabolic Associated Fatty Liver Disease (MAFLD) held in the vibrant city of Kaohsiung, Taiwan. We are delighted to have you here for this important gathering, dedicated to exploring the various facets of MAFLD and its impact on global health.

Our conference program covers a wide range of topics, including epidemiology, risk factors, and stratification of MAFLD. We will also discuss the diagnosis of steatosis and fibrosis, mechanisms of disease progression, and the metabolic characteristics associated with MAFLD development.

Additionally, we will examine the relationship between MAFLD and hepatocellular carcinoma (HCC), as well as the impact of HBV and HCV infections. Cross-talk sessions between cardiologists, diabetologists, and hepatologists will foster interdisciplinary collaboration.

Furthermore, non-pharmacological approaches, therapeutic targets, clinical trials, and policy reviews for MAFLD will be discussed, providing valuable insights into prevention and management strategies.

Once again, we extend our heartfelt welcome to each and every one of you. We hope that this conference will serve as a platform for fruitful discussions, knowledge sharing, and collaborative efforts towards a better understanding and management of MAFLD.

Thank you, and enjoy the conference!

Scientific Committee Chairperson

Pei-Jer Chen

Chair of Organizing Committee


Where we are

Our Sponsors


Co-organizared by